TrialJournal of neuro-oncology2024

Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma.

Phioanh Leia Nghiemphu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.